Prevalence of thyroid carcinoma in nodules with thy 3 cytology: the role of preoperative ultrasonography and strain elastography.
Strain elastography
Thy3 cytology
Thyroid carcinoma
Thyroid ultrasound
Journal
Thyroid research
ISSN: 1756-6614
Titre abrégé: Thyroid Res
Pays: England
ID NLM: 101469037
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
received:
06
12
2020
accepted:
23
03
2021
entrez:
10
4
2021
pubmed:
11
4
2021
medline:
11
4
2021
Statut:
epublish
Résumé
Fine needle aspiration (FNA) cytology, the gold standard in assessing thyroid nodules, is limited by its inability to determine the true risk of malignancy in Thy 3 nodules. Most patients with Thy3 cytology undergo surgery to establish a histologic diagnosis. The aims of this study were to evaluate the prevalence of malignancy in Thy3 nodules, to examine the ultrasound (US) characteristics that are associated with a high cancer risk and to assess the role of real-time strain elastography. Retrospective cohort study of 99 nodules with Thy3 cytology in 99 patients who underwent thyroidectomy over a three-year period. Grayscale US, Doppler and real-time strain elastography data were evaluated. Eighty-one nodules (81.82%) were benign, 18 (18.18%) were malignant, and almost all were papillary thyroid carcinoma (PTC). Univariable analysis revealed irregular margins (p = 0.02), ill-defined borders (p ≤ 0.001), a taller than wide shape (p ≤ 0.001) and the elasticity score (p = 0.02) as significant predictors of malignancy. Multivariable analysis showed that ill-defined borders and the elasticity score were significant and independent factors associated with malignancy. All soft nodules (elasticity scores 1-2) were benign (sensitivity 100%, specificity 33%, NPV 100%, and PPV 23%). There was a higher rate of malignancy in Thy3a nodules than in Thy3f nodules (42.86% versus 11.54%) (p ≤ 0.001). Irregular margins, ill-defined borders, a taller than wide shape and low elasticity were associated with malignancy. Elastography should be performed when evaluating Thy3 nodules.
Sections du résumé
BACKGROUND
BACKGROUND
Fine needle aspiration (FNA) cytology, the gold standard in assessing thyroid nodules, is limited by its inability to determine the true risk of malignancy in Thy 3 nodules. Most patients with Thy3 cytology undergo surgery to establish a histologic diagnosis. The aims of this study were to evaluate the prevalence of malignancy in Thy3 nodules, to examine the ultrasound (US) characteristics that are associated with a high cancer risk and to assess the role of real-time strain elastography.
METHODS
METHODS
Retrospective cohort study of 99 nodules with Thy3 cytology in 99 patients who underwent thyroidectomy over a three-year period. Grayscale US, Doppler and real-time strain elastography data were evaluated.
RESULTS
RESULTS
Eighty-one nodules (81.82%) were benign, 18 (18.18%) were malignant, and almost all were papillary thyroid carcinoma (PTC). Univariable analysis revealed irregular margins (p = 0.02), ill-defined borders (p ≤ 0.001), a taller than wide shape (p ≤ 0.001) and the elasticity score (p = 0.02) as significant predictors of malignancy. Multivariable analysis showed that ill-defined borders and the elasticity score were significant and independent factors associated with malignancy. All soft nodules (elasticity scores 1-2) were benign (sensitivity 100%, specificity 33%, NPV 100%, and PPV 23%). There was a higher rate of malignancy in Thy3a nodules than in Thy3f nodules (42.86% versus 11.54%) (p ≤ 0.001).
CONCLUSIONS
CONCLUSIONS
Irregular margins, ill-defined borders, a taller than wide shape and low elasticity were associated with malignancy. Elastography should be performed when evaluating Thy3 nodules.
Identifiants
pubmed: 33836771
doi: 10.1186/s13044-021-00098-x
pii: 10.1186/s13044-021-00098-x
pmc: PMC8033666
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Références
Sci Rep. 2019 Oct 18;9(1):14973
pubmed: 31628340
Endocrine. 2018 Mar;59(3):573-584
pubmed: 29350311
Sci Rep. 2017 Dec 21;7(1):18005
pubmed: 29269830
Radiol Oncol. 2018 Sep 27;52(4):370-376
pubmed: 30265655
Eur Thyroid J. 2019 Apr;8(2):83-89
pubmed: 31192147
Thyroid. 2018 Aug;28(8):1004-1012
pubmed: 29848195
J Thyroid Res. 2020 Mar 24;2020:3567658
pubmed: 32351678
Medicine (Baltimore). 2017 Apr;96(16):e6564
pubmed: 28422844
J Zhejiang Univ Sci B. 2017 Jul;18(7):555-566
pubmed: 28681580
Cancers (Basel). 2019 Oct 28;11(11):
pubmed: 31661800
Ann R Coll Surg Engl. 2018 Sep;100(7):545-550
pubmed: 29968505
Ultrasonography. 2019 Apr;38(2):106-124
pubmed: 30690960
Cancer Manag Res. 2018 Jul 23;10:2223-2229
pubmed: 30087580
N Engl J Med. 2012 Aug 23;367(8):705-15
pubmed: 22731672
Eur Thyroid J. 2015 Jun;4(2):123-8
pubmed: 26279998
Eur Thyroid J. 2015 Dec;4(4):246-51
pubmed: 26835428
Sci Rep. 2017 Dec 20;7(1):17901
pubmed: 29263433
Diagnostics (Basel). 2019 Sep 13;9(3):
pubmed: 31540296
Laryngoscope. 2011 Jun;121(6):1231-2
pubmed: 21557238
Thyroid. 2008 May;18(5):523-31
pubmed: 18466077
Ultraschall Med. 2013 Jun;34(3):238-53
pubmed: 23605169
Ultraschall Med. 2016 Jun;37(3):262-70
pubmed: 27070127
Cancer Control. 2017 Oct-Dec;24(5):1073274817729231
pubmed: 28975825
Eur Thyroid J. 2017 Sep;6(5):271-275
pubmed: 29071240
Genes (Basel). 2019 Sep 23;10(10):
pubmed: 31547603
Endocr Pract. 2016 May;22(5):622-39
pubmed: 27167915
Eur Thyroid J. 2017 Sep;6(5):225-237
pubmed: 29167761
Eur J Clin Invest. 2009 Aug;39(8):699-706
pubmed: 19601965
Front Endocrinol (Lausanne). 2020 Feb 18;11:53
pubmed: 32132976
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Clin Endocrinol Metab. 2011 Nov;96(11):3390-7
pubmed: 21880806
Med Sci Monit. 2018 Sep 08;24:6273-6279
pubmed: 30194820